Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.22M Hold
5,600
0.07% 309
2025
Q4
$1.28M Sell
5,600
-2,800
-33% -$638K 0.08% 317
2025
Q3
$1.94M Hold
8,400
0.12% 258
2025
Q2
$1.56M Buy
8,400
+6,400
+320% +$1.19M 0.09% 343
2025
Q1
$419K Buy
+2,000
New +$389K 0.03% 557
2023
Q4
Sell
-10,000
Closed -$1.49M 531
2023
Q3
$1.49M Buy
+10,000
New +$1.47M 0.19% 177
2022
Q4
Sell
-2,127
Closed -$285K 602
2022
Q3
$285K Buy
+2,127
New +$305K 0.04% 609
2020
Q2
Sell
-417,300
Closed -$31.8M 654
2020
Q1
$31.8M Buy
417,300
+319,900
+328% +$27.2M 2.52% 2
2019
Q4
$8.62M Sell
97,400
-359,684
-79% -$29.9M 0.53% 73
2019
Q3
$34.6M Sell
457,084
-748,167
-62% -$51.3M 2.06% 3
2019
Q2
$87.6M Buy
+1,205,251
New +$94.7M 5.18% 1
2015
Q4
Sell
-489,348
Closed -$26.6M 393
2015
Q3
$26.6M Buy
+489,348
New +$31.9M 0.6% 23
2015
Q2
Sell
-365,843
Closed -$21.4M 1312
2015
Q1
$21.4M Buy
+365,843
New +$22.1M 0.53% 26
2014
Q2
Sell
-368,679
Closed -$18.9M 1382
2014
Q1
$18.9M Buy
+368,679
New +$18.6M 0.46% 40
2013
Q3
Sell
-207,479
Closed -$8.58M 1466
2013
Q2
$8.58M Buy
+207,479
New +$9.07M 0.21% 114

Other funds holding ABBV

PDT Partners's ABBV Position: Q1 2026 in Review

PDT Partners held its AbbVie (ABBV) position steady in Q1 2026 at 5,600 shares worth $1.22M. The position accounts for 0.07% of the portfolio, ranked #309.

PDT Partners first reported a position in ABBV in Q2 2013 and has held it in 15 quarters since. The position peaked at $87.6M in Q2 2019. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • PDT Partners held 5,600 shares of AbbVie worth $1.22M as of Q1 2026.
  • PDT Partners left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.07% of PDT Partners's portfolio in Q1 2026, its #309 holding.
  • PDT Partners first reported a position in AbbVie in Q2 2013 and has held it in 15 quarters since.
  • PDT Partners's AbbVie position peaked at $87.6M in Q2 2019.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.